Please login to the form below

Not currently logged in

Ironwood promotes Dr Mark Currie

He moves up to chief scientific officer at the US pharma company

Ironwood Pharmaceuticals Dr Mark CurrieIronwood Pharmaceuticals has promoted Dr Mark Currie to senior vice president, chief scientific officer and president of R&D.

He previously led the Cambridge, Massachusetts-based company's R&D efforts, having joined the firm in 2002.

Prior to this he directed cardiovascular and central nervous system disease research as vice president of discovery research at Sepracor and before that served as director of arthritis and inflammation at Monsanto Company.

Ironwood's CEO Peter Hecht said: “Mark's outstanding contributions to Ironwood, including his expertise, leadership and superb judgment, are invaluable as we move our R&D efforts forward, growing our active pipeline and expanding our development efforts globally on behalf of our shareholders and the patients we aim to serve.”

Currie's academic research on the guanylate cyclase-C (GC-C) pathway laid the foundation for the discovery by Ironwood scientists of linaclotide.

Linaclotide was approved as a treatment for irritable bowel syndrome last year by regulators in Europe, where the drug is marketed as Constella by Almirall.

19th February 2013

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...